Califf's Ethics Letter Lists Conflicts He Averted
This article was originally published in The Tan Sheet
The waiting periods that followed the end of the FDA commissioner nominee’s affiliations with several pharma firms already have expired.
You may also be interested in...
Renowned clinical trialist and cardiologist will become deputy commissioner for medical products and tobacco, a complicated and challenging position.
The requirements to join the new real-time review pilot program strongly resemble those of the breakthrough designation, which could come as an unpleasant surprise for some sponsors.
System likely will evolve as post-pandemic world unfolds, but adds to list of agency programs expecting to continue using virtual platforms once in-person activities are no longer restricted by COVID-19.